We have focused our efforts on the use of lentiviral vectors to transfer genes to the rapamycin-resistant T cells. Using this approach, the majority of T cells in a given culture can be induced to express the new gene. We have also developed animal models to test the in vivo effect of these immuno-gene therapy strategies. Such models incorporate tumors and also evaluate graft-versus-host disease, which remains the main complication after allogeneic hematopoietic stem cell transplantation. To facilitate implementation of this project, we have entered into a cooperative research agreement with Lentigen Corporation to develop clinical protocols focusing on lentiviral delivery of suicide genes. Relevant cancer sites: Non-Hodgkins Lymphoma, Leukemia. Relevant Research Areas: Gene Therapy, Bone Marrow Transplantation, Organ Transplantation Research, Combined Treatment Modalities, Hematology/Lymph.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011219-05
Application #
8763409
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2013
Total Cost
$313,579
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Scaife, M; Pacienza, N; Au, B C Y et al. (2013) Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Ther 20:24-34
Wang, James C M; Felizardo, Tânia C; Au, Bryan C Y et al. (2013) Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J 10:240
Felizardo, Tania C; Foley, Jason; Steed, Kevin et al. (2013) Harnessing autophagy for cell fate control gene therapy. Autophagy 9:1069-79
Neschadim, Anton; Wang, James C M; Sato, Takeya et al. (2012) Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther 20:1002-13
Felizardo, T C; Wang, J C M; McGray, R A J et al. (2011) Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene Ther 18:986-95
Amarnath, Shoba; Mangus, Courtney W; Wang, James C M et al. (2011) The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3:111ra120
Scaife, Matthew D; Neschadim, Anton; Fowler, D H et al. (2009) Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opin Biol Ther 9:749-61
Symes, J C; Siatskas, C; Fowler, D H et al. (2009) Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. Cancer Gene Ther 16:439-52
Loisel-Meyer, Severine; Felizardo, Tania; Mariotti, Jacopo et al. (2009) Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther 8:692-702
Mossoba, Miriam E; Walia, Jagdeep S; Rasaiah, Vanessa I et al. (2008) Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther 16:607-17